APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients
Latest Information Update: 09 Apr 2024
At a glance
- Drugs Gefitinib (Primary) ; Osimertinib (Primary)
- Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms APPLE
- 06 Apr 2024 This trial has been completed in Poland according to European Clinical Trials Database record.
- 10 Mar 2024 According to an European Clinical Trials Database record, this trial has been completed in Slovenia.
- 28 Feb 2023 Results(n=103 ; of Arms B and C) assessing the feasibility of longitudinal plasma EGFR T790M monitoring for the best sequencing strategy of gefitinib and osimertinib published in the Annals of Oncology